Giant Cell Tumor of Bone, current treatments, and potential therapeutic alternatives

Giant Cell Tumor of Bone, current treatments, and potential therapeutic alternatives

Estrada-Villaseñor E.,1 Meneses A.,2 Valdés-Flores M.,3 Coutiño-Alcaraz JM.,4 Linares-González LM.,5 Olivos Meza A.,6 Ostoa-Saloma P.,7 Delgado Cedillo EA.,8 Landa Solís C.9

1National Institute of Rehabilitation. Pathology Service. Mexico City, México. 2National Cancer Institute. Managing Director. Mexico City, Mexico. 3National Institute of Rehabilitation. Assistant Manager Clinical Research in genetic service. Mexico City, México. 4National Institute of Rehabilitation. Pathology Service. Mexico City, Mexico. 5National Institute of Rehabilitation. Bone Tumors Service. Mexico City, Mexico. 6National Institute of Rehabilitation. Arthroscopy Service. Mexico City, México. 7Postgraduate degree in Biological Sciences, National Autonomous University of Mexico, University City, Mexico, Mexico City. 8National Institute of Rehabilitation. Bone Tumors Service. Mexico City, Mexico. 9National Institute of Rehabilitation. Tissue Engineering and Cell Therapy Unit. Mexico City, Mexico.

Giant cell tumor of bone (GCTB) is a primary bone tumor, locally aggressive. For many, a GCTB is considered a tumor with an unpredictable behavior, particularly regarding recurrences, pulmonary implants, and the possibility of primary malignancy. In terms of risk of recurrence, it is known that it is associated with the type of treatment used initially for the GCTB. The greater the number or recurrences, the greater the risk of pulmonary implants, and the greater the risk of malignant degeneration. Therefore, much of the prognosis of this tumor could be related to the type of initial treatment. Hence the importance of the treatment theme. This review includes a comparison between the various modalities for treatment in GCTB, considering the advantages and disadvantages of each one. Existing GCTB treatments are not 100% safe and effective at the same time. and this is the reason why the search for other treatment modalities should continue to offer a better oncologic and functional outcome to patients. In the end of this review, based on research work, we also mention other possible therapeutic options that could be explored and used in the future for GCT treatment.

Keywords: Bone tumors, Giant cell tumor of bone, treatment, Denosumab, Bisphosphonates.

Free Full-text PDF

How to cite this article:
Estrada-Villaseñor E.,Meneses A.,Valdés-Flores M.,Coutiño-Alcaraz JM.,Linares-González LM., Olivos Meza A.,Ostoa-Saloma P., Delgado Cedillo EA.,Landa Solís C. Giant Cell Tumor of Bone, current treatments, and potential therapeutic alternatives.American Journal of Cancer Research and Reviews, 2020,4:13. DOI:10.28933/ajocrr-2020-10-0205


1. McCarthy EF. Giant-cell tumor of bone: an historical perspective. Clin Orthop Relat Res. 1980[153]:14-25.
2. Jo VY, Fletcher CD. WHO classification of soft tissue tumours: an update based on the 2013 [4th] edition. Pathology. 2014;46[2]:95-104. 10.1097/pat.0000000000000050
3. Roessner A, Smolle M, Haybäck J. [Giant cell tumor of bone : Morphology, molecular pathogenesis, and differential diagnosis]. Pathologe. 2020;41[2]:134-42. 10.1007/s00292-020-00760-5
4. Harrleson J. Bone tumors: general aspects and data on 6,221 cases. Annals of Surgery. 1980;191[4]:511.
5. Jain K, Sunila RR, Mruthyunjaya C, Gadiyar H, Manjunath G. Bone tumors in a tertiary care hospital of south India: A review 117 cases. Indian journal of medical and paediatric oncology: official journal of Indian Society of Medical & Paediatric Oncology. 2011;32[2]:82.
6. Liede A, Hernandez RK, Tang E-T, Li C, Bennett B, Wong SS, et al. Epidemiology of benign giant cell tumor of bone in the Chinese population. Journal of bone oncology. 2018;12:96-100.
7. Estrada-Villaseñor E, Linares-González L, Delgado-Cedillo E, González-Guzmán R, Rico-Martínez G. Prevalencia y características clínico-patológicas del tumor de células gigantes. Acta ortopédica mexicana. 2015;29[6]:295-8.
8. Niu X, Xu H, Inwards CY, Li Y, Ding Y, Letson GD, et al. Primary bone tumors: epidemiologic comparison of 9200 patients treated at Beijing Ji Shui Tan hospital, Beijing, China, with 10 165 patients at Mayo Clinic, Rochester, Minnesota. Archives of Pathology and Laboratory Medicine. 2015;139[9]:1149-55.
9. Yang Y, Huang Z, Niu X, Xu H, Li Y, Liu W. Clinical characteristics and risk factors analysis of lung metastasis of benign giant cell tumor of bone. J Bone Oncol. 2017; 7: 23–8.
10. Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH. Giant cell tumor of bone: risk factors for recurrence. Clinical Orthopaedics and Related Research®. 2011;469[2]:591-9.
11. Alberghini M, Kliskey K, Krenacs T, Picci P, Kindblom L, Forsyth R, et al. Morphological and immunophenotypic features of primary and metastatic giant cell tumour of bone. Virchows Archiv. 2010;456[1]:97-103.
12. Li D, Zhang J, Li Y, Xia J, Yang Y, Ren M, et al. Surgery methods and soft tissue extension are the potential risk factors of local recurrence in giant cell tumor of bone. World journal of surgical oncology. 2016;14[1]:114.
13. Cheng D-d, Hu T, Zhang H-z, Huang J, Yang Q-c. Factors affecting the recurrence of giant cell tumor of bone after surgery: a clinicopathological study of 80 cases from a single center. Cellular Physiology and Biochemistry. 2015;36[5]:1961-70.
14. Teixeira L, Vilela J, Miranda RH, Gomes AH, Costa FA, de Faria VC. Giant cell tumors of bone: nonsurgical factors associated with local recurrence. Acta Orthop Traumatol Turc. 2014;48[2]:136.
15. Rico-Martínez G, Linares-González L, Delgado-Cedillo E, Espejo-Sánchez G, Cerrada-Moreno L, Clara-Altamirano M. Long-term results of the treatment of a giant cell tumor with en-bloc resection and unconventional hip arthroplasty with ipsilateral knee arthrodesis. Clinical case report and literature review. Acta Ortopédica Mexicana. 2013;27[4]:250-5.
16. Saini R, Bali K, Bachhal V, Mootha AK, Dhillon MS, Gill SS. En bloc excision and autogenous fibular reconstruction for aggressive giant cell tumor of distal radius: a report of 12 cases and review of literature. Journal of orthopaedic surgery and research. 2011;6[1]:14.
17. Knochentumoren A. Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy. JBJS. 2008;90[5]:1060-7.
18. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proceedings of the National Academy of Sciences. 1999;96[7]:3540-5.
19. Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay J-Y, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. The lancet oncology. 2010;11[3]:275-80.
20. Rutkowski P, Ferrari S, Grimer RJ, Stalley PD, Dijkstra SP, Pienkowski A, et al. Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone. Annals of surgical oncology. 2015;22[9]:2860-8.
21. Traub F, Singh J, Dickson BC, Leung S, Mohankumar R, Blackstein ME, et al. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone. European Journal of Cancer. 2016;59:1-12.
22. Thornley P, Habib A, Bozzo A, Evaniew N, Ghert M. The role of denosumab in the modern treatment of giant cell tumor of bone. Jbjs Reviews. 2017;5[4].
23. FELDMAN F, CASARELLA WJ, DICK HM, HOLLANDER BA. Selective intra-arterial embolization of bone tumors: a useful adjunct in the management of selected lesions. American Journal of Roentgenology. 1975;123[1]:130-9.
24. Nakanishi K, Osuga K, Hori S, Hamada K, Hashimoto N, Araki N, et al. Transarterial embolization [TAE] of sacral giant cell Tumor [GCT] using spherical parmanent embolic material superabsorbant polymer microsphere [SAP-MS]. Springerplus. 2013;2[1]:666.
25. Hosalkar HS, Jones KJ, King JJ, Lackman RD. Serial arterial embolization for large sacral giant-cell tumors: mid-to long-term results. Spine. 2007;32[10]:1107-15.
26. He Sh, Xu W, Sun Zw, Liu Wb, Liu Yj, Wei Hf, et al. Selective arterial embolization for the treatment of sacral and pelvic giant cell tumor: a systematic review. Orthopaedic Surgery. 2017;9[2]:139-44.
27. Onishi H, Kaya M, Wada T, Nagoya S, Sasaki M, Yamashita T. Giant cell tumor of the sacrum treated with selective arterial embolization. International journal of clinical oncology. 2010;15[4]:416-9.
28. Stewart FW, Coley BL, Farrow JH. Malignant giant cell tumor of bone. The American journal of pathology. 1938;14[5]:515.
29. Ellis F. Treatment of osteoclastoma by radiation. The Journal of bone and joint surgery British volume. 1949;31[2]:268-80.
30. Chakravarti A, Spiro IJ, Hug EB, Mankin HJ, Efird JT, Suit HD. Megavoltage radiation therapy for axial and inoperable giant-cell tumor of bone. JBJS. 1999;81[11]:1566-73.
31. Ruka W, Rutkowski P, Morysiński T, Nowecki Z, Zdzienicki M, Makula D, et al. The megavoltage radiation therapy in treatment of patients with advanced or difficult giant cell tumors of bone. International Journal of Radiation Oncology* Biology* Physics. 2010;78[2]:494-8.
32. Miszczyk L, Wydmański J, Spindel J. Efficacy of radiotherapy for giant cell tumor of bone: given either postoperatively or as sole treatment. International Journal of Radiation Oncology* Biology* Physics. 2001;49[5]:1239-42.
33. Russell R, Watts N, Ebetino F, Rogers M. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporosis international. 2008;19[6]:733-59.
34. Chang SS, Suratwala SJ, Jung KM, Doppelt JD, Zhang HZ, Blaine TA, et al. Bisphosphonates may reduce recurrence in giant cell tumor by inducing apoptosis. Clinical Orthopaedics and Related Research®. 2004;426:103-9.
35. Shibuya I, Takami M, Miyamoto A, Karakawa A, Dezawa A, Nakamura S, et al. In vitro study of the effects of denosumab on giant cell tumor of bone: comparison with zoledronic acid. Pathology & Oncology Research. 2019;25[1]:409-19.
36. Chaudhary P, Khadim H, Gajra A, Damron T, Shah C. Bisphosphonate therapy is effective in the treatment of sacral giant cell tumor. Oncology Research and Treatment. 2011;34[12]:702-4.
37. Tse LF, Wong KC, Kumta SM, Huang L, Chow TC, Griffith JF. Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case–control study. Bone. 2008;42[1]:68-73.
38. Xu W, Wang Y, Wang J, Yang X, Liu W, Zhou W, et al. Long-term administration of bisphosphonate to reduce local recurrence of sacral giant cell tumor after nerve-sparing surgery. Journal of Neurosurgery: Spine. 2017;26[6]:716-21.
39. Dubey S, Rastogi S, Sampath V, Khan SA, Kumar A. Role of intravenous zoledronic acid in management of giant cell tumor of bone-A prospective, randomized, clinical, radiological and electron microscopic analysis. Journal of Clinical Orthopaedics and Trauma. 2019;10[6]:1021-6.
40. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor-and lymphocyte-induced vascular responses. Cancer research. 1987;47[19]:5155-61.
41. Kaiser U, Neumann K, Havemann K. Generalised giant-cell tumour of bone: Successful treatment of pulmonary metastases with interferon α, a case report. Journal of cancer research and clinical oncology. 1993;119[5]:301-3.
42. Wei F, Liu X, Liu Z, Jiang L, Dang G, Ma Q, et al. Interferon alfa-2b for recurrent and metastatic giant cell tumor of the spine: report of two cases. Spine. 2010;35[24]:E1418-E22.
43. Young PS, Bell SW, Mahendra A. The evolving role of computer-assisted navigation in musculoskeletal oncology. Bone Joint J. 2015;97-b[2]:258-64. 10.1302/0301-620x.97b2.34461
44. Farfalli GL, Albergo JI, Piuzzi NS, Ayerza MA, Muscolo DL, Ritacco LE, et al. Is Navigation-guided En Bloc Resection Advantageous Compared With Intralesional Curettage for Locally Aggressive Bone Tumors? Clinical Orthopaedics and Related Research. 2018;476[3]:511.
45. Greenberg DD, Lee FY. Bisphosphonate-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Tumor of Bone. American journal of clinical oncology. 2019;42[3]:231-7.
46. Gitelis S, Mallin BA, Piasecki P, Turner F. Intralesional excision compared with en bloc resection for giant-cell tumors of bone. The Journal of Bone and Joint surgery American Volume. 1993;75[11]:1648-55.
47. Jamshidi K, Bahrabadi M, Bagherifard A, Mohamadpour M. Surgical treatment outcome of giant cell tumor of distal ulna: En bloc resection vs. curettage and bone graft. Medical journal of the Islamic Republic of Iran. 2018;32:44.
48. Wysocki RW, Soni E, Virkus WW, Scarborough MT, Leurgans SE, Gitelis S. Is intralesional treatment of giant cell tumor of the distal radius comparable to resection with respect to local control and functional outcome? Clinical Orthopaedics and Related Research®. 2015;473[2]:706-15.
49. Errani C, Ruggieri P, Asenzio MAN, Toscano A, Colangeli S, Rimondi E, et al. Giant cell tumor of the extremity: a review of 349 cases from a single institution. Cancer treatment reviews. 2010;36[1]:1-7.
50. Errani C, Tsukamoto S, Ciani G, Donati DM. Present day controversies and consensus in curettage for giant cell tumor of bone. Journal of Clinical Orthopaedics and Trauma. 2019;10[6]:1015-20.
51. Balke M, Schremper L, Gebert C, Ahrens H, Streitbuerger A, Koehler G, et al. Giant cell tumor of bone: treatment and outcome of 214 cases. Journal of cancer research and clinical oncology. 2008;134[9]:969-78.
52. Dürr H, Maier M, Jansson V, Baur A, Refior H. Phenol as an adjuvant for local control in the treatment ofgiant cell tumour of the bone. European Journal of Surgical Oncology. 1999;25[6]:610-8.
53. Omlor GW, Lange J, Streit M, Gantz S, Merle C, Germann T, et al. Retrospective analysis of 51 intralesionally treated cases with progressed giant cell tumor of the bone: local adjuvant use of hydrogen peroxide reduces the risk for tumor recurrence. World journal of surgical oncology. 2019;17[1]:73.
54. Saiz P, Virkus W, Piasecki P, Templeton A, Shott S, Gitelis S. Results of giant cell tumor of bone treated with intralesional excision. Clinical Orthopaedics and Related Research [1976-2007]. 2004;424:221-6.
55. Abdelrahman M, Bassiony AA, Shalaby H, Assal MK. Cryosurgery and impaction subchondral bone graft for the treatment of giant cell tumor around the knee. HSS journal. 2009;5[2]:123-8.
56. Alkalay D, Kollender Y, Mozes M, Meller I. Giant cell tumors with intraarticular fracture Two-stage local excision, cryosurgery and cementation in 5 patients with distal femoral tumor followed for 2–4 years. Acta Orthopaedica Scandinavica. 1996;67[3]:291-4.
57. Wittig JC, Simpson BM, Bickels J, Kellar-Graney KL, Malawer MM. Giant cell tumor of the hand: superior results with curettage, cryosurgery, and cementation. The Journal of hand surgery. 2001;26[3]:546-55.
58. Scoccianti G, Totti F, Scorianz M, Baldi G, Roselli G, Beltrami G, et al. Preoperative Denosumab with curettage and Cryotherapy in Giant cell tumor of bone: is there an increased risk of local recurrence? Clinical orthopaedics and related research. 2018;476[9]:1783.
59. Luengo-Alonso G, Mellado-Romero M, Shemesh S, Ramos-Pascua L, Pretell-Mazzini J. Denosumab treatment for giant-cell tumor of bone: a systematic review of the literature. Archives of orthopaedic and trauma surgery. 2019;139[10]:1339-49.
60. Palmerini E, Chawla N, Ferrari S, Sudan M, Picci P, Marchesi E, et al. Denosumab in advanced/unresectable giant-cell tumour of bone [GCTB]: for how long? European Journal of Cancer. 2017;76:118-24.
61. Broehm CJ, Garbrecht EL, Wood J, Bocklage T. Two cases of sarcoma arising in giant cell tumor of bone treated with denosumab. Case reports in medicine. 2015;2015.
62. Lin PP, Guzel VB, Moura MF, Wallace S, Benjamin RS, Weber KL, et al. Long‐term follow‐up of patients with giant cell tumor of the sacrum treated with selective arterial embolization. Cancer. 2002;95[6]:1317-25.
63. Caudell JJ, Ballo MT, Zagars GK, Lewis VO, Weber KL, Lin PP, et al. Radiotherapy in the management of giant cell tumor of bone. International Journal of Radiation Oncology* Biology* Physics. 2003;57[1]:158-65.
64. Ma Y, Xu W, Yin H, Huang Q, Liu T, Yang X, et al. Therapeutic radiotherapy for giant cell tumor of the spine: a systemic review. European Spine Journal. 2015;24[8]:1754-60.
65. Shi M, Chen L, Wang Y, Wang W, Zhang Y, Yan S. Effect of bisphosphonates on local recurrence of giant cell tumor of bone: a meta-analysis. Cancer Management and Research. 2019;11:669.
66. Sedghizadeh PP, Kumar SK, Gorur A, Schaudinn C, Shuler CF, Costerton JW. Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy. The Journal of the American Dental Association. 2009;140[10]:1259-65.
67. Sellmeyer DE. Atypical fractures as a potential complication of long-term bisphosphonate therapy. Jama. 2010;304[13]:1480-4.
68. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005;23[34]:8580-7.
69. Migliorati CA, Woo S-B, Hewson I, Barasch A, Elting LS, Spijkervet FK, et al. A systematic review of bisphosphonate osteonecrosis [BON] in cancer. Supportive care in cancer. 2010;18[8]:1099-106.